Prognostic impact of epidermal growth factor receptor (EGFR) mutations in lung cancer /
Fatma Hassan Abdelraouf
Prognostic impact of epidermal growth factor receptor (EGFR) mutations in lung cancer / تأثيرطفرات مستقبل عامل نمو البشرة على مدى تطور مرض سرطان الرئة Fatma Hassan Abdelraouf ; Supervised Taghrid Mohamed Gaafar , Mary Obrien , Ayatallah Amir Nassef - Cairo : Fatma Hassan Abdelraouf , 2014 - 196 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Molecular biomarkers have been investigated in non-small cell lung cancer (NSCLC) and targeted treatments in advanced disease are established. However, there are no established targeted therapies at the moment for small cell lung cancer (SCLC). The aim of this study was to examine for the presence of known molecular targets in patients with SCLC and their prognostic effect. A panel of histopathologically proven FFPE specimens of SCLC were analysed for EGFR, KRAS, NRAS, BRAFmutations, ALK gene rearrangements and MET amplification. EGFR and KRAS testing were done using real time - polymerase chain reaction (RT - PCR cobas®), BRAF and NRAS using multiplex PCR and capillary electrophoresis-single strand conformation analysis (CE - SSCA) and ALK and MET using fluorescent in situ hybridization (FISH). Any positive results were repeated for confirmation. Any inconsistent results were sequenced using the direct sanger sequencing
EGFR Molecular biomarkers Small cell lung cancer
Prognostic impact of epidermal growth factor receptor (EGFR) mutations in lung cancer / تأثيرطفرات مستقبل عامل نمو البشرة على مدى تطور مرض سرطان الرئة Fatma Hassan Abdelraouf ; Supervised Taghrid Mohamed Gaafar , Mary Obrien , Ayatallah Amir Nassef - Cairo : Fatma Hassan Abdelraouf , 2014 - 196 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Molecular biomarkers have been investigated in non-small cell lung cancer (NSCLC) and targeted treatments in advanced disease are established. However, there are no established targeted therapies at the moment for small cell lung cancer (SCLC). The aim of this study was to examine for the presence of known molecular targets in patients with SCLC and their prognostic effect. A panel of histopathologically proven FFPE specimens of SCLC were analysed for EGFR, KRAS, NRAS, BRAFmutations, ALK gene rearrangements and MET amplification. EGFR and KRAS testing were done using real time - polymerase chain reaction (RT - PCR cobas®), BRAF and NRAS using multiplex PCR and capillary electrophoresis-single strand conformation analysis (CE - SSCA) and ALK and MET using fluorescent in situ hybridization (FISH). Any positive results were repeated for confirmation. Any inconsistent results were sequenced using the direct sanger sequencing
EGFR Molecular biomarkers Small cell lung cancer